Viatris’ Avastin biosimilar faces delay
The Food and Drug Administration has informed Biocon Biologics and Mylan, a subsidiary of Viatris, of a deferred action on the biologics license application for MYL-14020, a biosimilar to Roche's Avastin (bevacizumab).